The first-ever cohort study to describe outcomes through adolescence among neonates with aortic atresia according to initial treatment finds a survival edge with primary heart transplant.
Cleveland Clinic Children’s is dedicated to delivering the highest quality medical care, for every care in the world. To mark this continued advancement, this post focuses on specialty outcomes measures.
For any clinician with an interest in congenitally corrected transposition of the great arteries (CCTGA), this 2.5-day October CME event is can’t-miss.
Two experts share key takeaways from one of the most important congenital heart surgery trials of the past decade.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A large 20-year-old registry studying this congenital heart anomaly is starting to yield insights, and complementary prospective and retrospective Cleveland Clinic studies of adults with AAOCA promise to be useful adjuncts.
The move broadens the five-year-old relationship to more fully encompass both organizations’ pediatric and adult congenital cardiology programs.
We’re joining forces with Boston Children’s Hospital for a day and a half of powerhouse instruction on adult and pediatric CHD from multidisciplinary perspectives.
There’s currently no heart valve prosthesis small enough to fit in a newborn with a congenital mitral valve defect. A Cleveland Clinic team aims to change that with a novel device designed to “grow” with the child.
Thomas E. Fagan, MD, joined Cleveland Clinic Children’s as Director of Pediatric and Congenital Cardiac Catheterization Laboratory in 2018. He sat down with CQD to discuss the team’s approach to congenital heart disease.
In congenital heart surgery, experience begets innovation. Successful development of a novel trans-conal unroofing approach to a rare heart defect is a case in point.